Nearly all of the rather substantial effort devoted to MCH-based drug development has been directed toward producing MCHR1 antagonists with a clinical application in obesity, though several peptide MCHR1 agonists have also been identified. This evidence concerns the gene MCHR1 and obesity due to melanocortin 4 receptor deficiency.